Tracking the diabetes drug market

[ad_1]

GLP-1 drugs have grown in popularity and Aspen is betting on contracts for the medications to boost future earnings. To discuss the evolution of the highly effective diabetes and obesity drugs, Business Day TV sat down with Aspen’s Stavros Nicolaou.



[ad_2]

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *